(19)
(11) EP 4 539 854 A1

(12)

(43) Date of publication:
23.04.2025 Bulletin 2025/17

(21) Application number: 23824781.1

(22) Date of filing: 14.06.2023
(51) International Patent Classification (IPC): 
A61K 31/662(2006.01)
A61P 25/28(2006.01)
A61P 43/00(2006.01)
 A61P 25/00(2006.01)
A61P 5/14(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/662
(86) International application number:
PCT/US2023/068428
(87) International publication number:
WO 2023/245055 (21.12.2023 Gazette 2023/51)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 15.06.2022 US 202263352350 P

(71) Applicant: Viking Therapeutics, Inc.
San Diego, CA 92121 (US)

(72) Inventors:
  • LIAN, Brian
    Rancho Santa Fe, CA 92067 (US)
  • BARKER, Geoff
    San Diego, CA 92121 (US)

(74) Representative: Dörries, Hans Ulrich 
df-mp Patentanwälte Rechtsanwälte PartG mbB Theatinerstraße 16
80333 München
80333 München (DE)

   


(54) THYROID BETA-AGONIST DOSING REGIMENS FOR THE TREATMENT OF X-ALD